Immunicum AB: Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September

Press Release

22 August 2017

Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September

Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, today announced that Immunicum leadership will present the Company at several upcoming investor and partnering conferences in August and September.

Swedish-American Life Science Summit 2017
Date: August 23 - 25, 2017
Presentation Time: August 25, 12:00 pm Central European Time
Venue: Nasdaq Stockholm, Tullvaktsvägen 15, Stockholm, Sweden

Pareto Securities' 8th Annual Healthcare Conference
Date: September 7, 2017
Presentation Time: 12:15 pm Central European Time
Venue: Conference 7A Strandvägen 7A Stockholm, Sweden

24th Annual NewsMakers in the Biotech Industry
Date: September 8, 2017
Presentation Time: 8:30 - 8:55 am Eastern Standard Time
Venue: Millennium Broadway Hotel & Conference Center, New York, NY

Rodman & Renshaw 19th Annual Global Investment Conference
Date: September 10 - 12, 2017
Presentation Time: September 11, 5:30 - 5:55 pm Eastern Standard Time
Venue: Lotte New York Palace Hotel, New York, NY

Nordic Life Science Days 2017
Date: September 12 - 14, 2017
Presentation Time: September 13, 10:40 am Central European Time
Venue: Malmömässan, Mässgatan 6, Hyllie, Malmö, Sweden

RedEye Cancer Immunotherapy "Special Event"
Date: September 21, 2017
Presentation Time: TBD - time will be posted on Immunicum website
Venue: Redeye, Mäster Samuelsgatan 42, 10 tr, Stockholm, Sweden

BioPharm America
Date: September 26 - 27, 2017
Presentation Time: TBD - time will be posted on Immunicum website
Venue: Sheraton Boston Hotel, Boston, MA

17th Annual Sachs Biotech in Europe Forum
Date: September 26 - 27, 2017
Presentation Time: September 27, 12:00 pm Central European Time
Venue: Congress Center Basel, Switzerland

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: [phone]
E-mail: [e-mail] (mailto:[e-mail])

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: [e-mail] (mailto:[e-mail])

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: [phone] or [phone]
E-mail: [e-mail] (mailto:[e-mail]) or [e-mail] (mailto:[e-mail])

The Company's Certified Adviser is Redeye AB
Telephone: [phone]
www.redeye.se (http://www.redeye.se)

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com (http://www.immunicum.com)

 

20170822_Immunicum_August and September Conferences_EN_Final (http://hugin.info/171739/R/2128345/812839.pdf)

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire